Evaxion Biotech (NASDAQ:EVAX) has partnered with Afrigen Biologics to develop a prophylactic vaccine based on Evaxion's EDEN-discovered gonorrhea targets. The partnership aims to address a serious global medical need as there is currently no vaccine for gonorrhea. The EDEN-discovered antigens have shown high levels of protection in preclinical studies. The partners will negotiate a subsequent agreement for clinical development and commercialization after the validation phase. Evaxion Biotech also initiated a new pipeline program, EVX-B3, in collaboration with an undisclosed pharmaceutical company.